Value Chain Definition on the Diagnostic Medicine in Brazil.¶

The value chain of the Diagnostic Medicine industry in Brazil is a complex network of interconnected activities that collectively deliver diagnostic services to patients and healthcare providers. It encompasses the flow of products, services, information, and finances, starting from the development and manufacturing of diagnostic tools to the final delivery and interpretation of results and subsequent impact on patient care. Understanding this chain is crucial for analyzing the industry's structure, identifying key players, and recognizing bottlenecks and opportunities.

Value Chain outline¶

The value chain in the Diagnostic Medicine sector in Brazil can be broken down into several comprehensive steps, reflecting the journey from the initial development of diagnostic technologies to the final impact on patient health.

Identification and description of each step in the value chain.¶

Research, Development, and Manufacturing: This initial step involves the ideation, research, development, and large-scale production of diagnostic equipment, instruments, kits, reagents, and related consumables. It is the foundation of the value chain, providing the necessary tools for diagnostic procedures.
- Identification and description of segments for each step of the value chain.
  - Segment: In Vitro Diagnostics (IVD) Manufacturing. Focuses on producing reagents, kits, calibrators, and controls used in laboratory tests.
  - Segment: Medical Imaging Equipment Manufacturing. Concentrates on the production of machines like MRI, CT scanners, X-ray machines, and ultrasound devices.
  - Segment: Anatomical Pathology Supplies Manufacturing. Involves producing reagents, stains, and equipment specifically for processing and analyzing tissue samples.
  - Segment: Software and IT Solutions Development. Dedicated to creating Laboratory Information Systems (LIS), Picture Archiving and Communication Systems (PACS), and other software for managing diagnostic workflows and data.
- List of types of players in each segment
  - Multinational manufacturers with local subsidiaries or distributors.
  - National manufacturers.
  - Research institutions and universities involved in developing new diagnostic technologies.
- Detailed description of the main activities within each segment.
  - IVD Manufacturing: Research and development of new assays and tests; production of chemical reagents, biological components, and kits; quality control and assurance; regulatory approval processes (e.g., ANVISA in Brazil).
  - Medical Imaging Equipment Manufacturing: Designing and engineering imaging modalities; manufacturing complex machinery; software development for image acquisition and processing; installation and maintenance services; obtaining regulatory certifications.
  - Anatomical Pathology Supplies Manufacturing: Developing and producing specialized reagents and stains; manufacturing tissue processing equipment; ensuring product quality and consistency for accurate diagnosis.
  - Software and IT Solutions Development: Designing and programming software for laboratory and image management; integrating systems with diagnostic equipment; ensuring data security and compliance with regulations (e.g., LGPD); providing technical support and updates.
- List examples of key players with detailed profiles.
  - Roche Diagnostics: A major global player with a significant presence in Brazil, offering a broad portfolio of IVD tests and instruments across various disciplines like clinical chemistry, immunology, molecular diagnostics, and point of care. They serve a large number of laboratories in Brazil.
  - Vyttra Diagnósticos: Described as a complete platform for development, manufacturing, and distribution of diagnostic solutions in Brazil, with proprietary technology and a focus on national industry. They offer solutions in hematology, biochemistry, immunology, VHS, and point of care.
  - Biocon Diagnóstica: An Brazilian industry focused on manufacturing and commercialization of IVD products for human and animal lines, importing equipment and general laboratory products. They are certified by ANVISA and have a distribution network across Brazil.
  - Labtest Diagnóstica: Mentioned as a provider of materials for laboratories, including manufacturing their own reagents and chemical solutions.
  - Gold Analisa Diagnóstica: A Brazilian company producing and commercializing IVD reagents, primarily in clinical biochemistry.
  - Siemens Healthineers: A global leader in medical technology, likely involved in providing imaging equipment and potentially IVD solutions in Brazil, though not explicitly detailed in the provided snippets.
  - GE Healthcare: Another major global provider of medical technology, including imaging equipment, with operations in Brazil.
  - Philips Healthcare: A global company offering a range of healthcare technology, including diagnostic imaging solutions, active in the Brazilian market.
Distribution and Commercialization: This step involves the logistics, warehousing, sales, and marketing of diagnostic products from manufacturers to the points of service delivery (laboratories, hospitals, clinics).
- Identification and description of segments for each step of the value chain.
  - Segment: Wholesale Distribution. Large-scale storage and transport of diagnostic products from manufacturers to smaller distributors or directly to large service providers.
  - Segment: Specialized Distribution. Focuses on specific types of products (e.g., only imaging equipment, only reagents) or specific geographic regions.
  - Segment: Direct Sales. Manufacturers selling directly to large laboratory networks or hospital groups.
- List of types of players in each segment
  - Large national distributors.
  - Regional distributors.
  - Manufacturer's sales teams.
  - Representatives and brokers.
- Detailed description of the main activities within each segment.
  - Wholesale Distribution: Inventory management, cold chain logistics for reagents, transportation, regulatory compliance for product handling.
  - Specialized Distribution: Providing technical expertise and support related to specific product lines, managing complex installations for equipment, offering training.
  - Direct Sales: Building relationships with key clients, negotiating contracts, providing customized solutions, offering post-sales support.
- List examples of key players with detailed profiles.
  - Vyttra Diagnósticos: Acts as a platform that includes distribution of diagnostic solutions.
  - Biocon Diagnóstica: Utilizes a network of distribution and regional representatives across Brazil.
  - Sullab: Positions itself as a major distributor of products and services for diagnostics and research in Brazil, with a strong presence in the Southern region.
  - DNEDX: Highlighted as a distributor in the Brazilian market, working with various segments including clinical laboratories, anatomical pathology, and veterinary, offering a portfolio of products.
  - Inopat: Began by identifying a need for new product options in Brazil, particularly for surgical pathology, and focuses on representing and distributing innovative diagnostic solutions.
  - Erba Mannheim Brasil: Offers IVD solutions with a focus on accessibility and has a technical team to support laboratories.
Diagnostic Service Provision: This is the core of the value chain where diagnostic tests and procedures are performed on patient samples or bodies.
- Identification and description of segments for each step of the value chain.
  - Segment: Clinical Analysis Laboratories. Perform a wide range of tests on blood, urine, feces, and other body fluids (biochemistry, hematology, immunology, microbiology, molecular biology).
  - Segment: Diagnostic Imaging Centers. Conduct imaging exams using technologies like X-ray, ultrasound, CT, MRI, and nuclear medicine.
  - Segment: Anatomical Pathology Laboratories. Process and analyze tissue biopsies and cytological samples for diagnosing diseases like cancer.
  - Segment: Genetics and Molecular Diagnostics Laboratories. Specialize in genetic testing and molecular analysis for inherited diseases, infectious agents, and personalized medicine.
  - Segment: Point-of-Care Testing (POCT) Providers. Offer rapid diagnostic tests performed outside of a central laboratory, often closer to the patient.
- List of types of players in each segment
  - Large national laboratory networks (private).
  - Medium and small independent laboratories (private).
  - Hospital-based laboratories and imaging centers (public and private).
  - Public health laboratories.
  - Diagnostic units within clinics and physician's offices.
- Detailed description of the main activities within each segment.
  - Clinical Analysis Laboratories: Sample collection, preparation, and analysis; performing a wide array of tests; quality control; generating and reporting results; providing technical and scientific咨询 to physicians. They manage pre-analytical, analytical, and post-analytical phases.
  - Diagnostic Imaging Centers: Patient preparation, operating imaging equipment, acquiring and processing images, generating reports, providing teleradiology services.
  - Anatomical Pathology Laboratories: Tissue processing, slide preparation, microscopic examination, performing immunohistochemistry and other special stains, generating pathology reports, participating in multidisciplinary discussions.
  - Genetics and Molecular Diagnostics Laboratories: DNA/RNA extraction, performing PCR and sequencing, analyzing genetic data, interpreting results in the context of clinical information, genetic counseling.
  - Point-of-Care Testing Providers: Performing rapid tests in various settings (clinics, pharmacies, homes), ensuring proper sample collection and handling, providing immediate results.
- List examples of key players with detailed profiles.
  - Dasa: One of the largest diagnostic medicine companies in Brazil, operating a vast network of clinical analysis laboratories and imaging centers under various brands. They offer a wide range of diagnostic services, including analyses, imaging, pathology, genetics, and support for other laboratories.
  - Grupo Fleury: A major player in the Brazilian diagnostic medicine market, known for its high-quality services and focus on specialized testing. Merged with Hermes Pardini, creating a significant force in the sector.
  - Sabin Medicina Diagnóstica: A large laboratory network with significant presence across Brazil, actively expanding through acquisitions.
  - Afip Medicina Diagnóstica: Highlighted as the largest clinical analysis laboratory in the SUS outpatient network for over ten years, demonstrating a strong presence in the public sector. They also launched a business unit focused on supporting hospitals and laboratories (B2B).
  - Rede D'Or São Luiz: While primarily a hospital network, they have significant diagnostic imaging and laboratory services integrated within their hospitals.
Healthcare Service Delivery and Utilization: This step represents how diagnostic services are integrated into the broader healthcare system and accessed by patients and physicians for diagnosis, treatment planning, and monitoring.
- Identification and description of segments for each step of the value chain.
  - Segment: Public Healthcare System (SUS). Diagnostic services provided within public hospitals and clinics or outsourced to private providers.
  - Segment: Supplementary Health System. Diagnostic services covered by private health insurance plans and utilized by beneficiaries in accredited or proprietary networks.
  - Segment: Private Self-Pay. Patients paying directly for diagnostic services outside of insurance coverage.
  - Segment: Corporate and Occupational Health. Diagnostic testing for pre-employment, periodic check-ups, and occupational health surveillance.
- List of types of players in each segment
  - Public hospitals and health units.
  - Private hospitals and clinics.
  - Health insurance operators (operadoras de saúde).
  - Companies providing occupational health services.
  - Patients (as consumers of services).
  - Physicians (requesting and interpreting exams).
- Detailed description of the main activities within each segment.
  - Public Healthcare System (SUS): Providing access to essential diagnostic tests for the population, managing public laboratories and imaging centers, contracting private providers to complement capacity.
  - Supplementary Health System: Contracting with diagnostic service providers, managing patient eligibility and claims, negotiating reimbursement rates, offering different plan options with varying coverage.
  - Private Self-Pay: Patients seeking services directly, often for convenience, specialized tests, or in areas with limited public/supplementary access.
  - Corporate and Occupational Health: Establishing agreements with diagnostic providers for employee testing, managing health programs.
- List examples of key players with detailed profiles.
  - Brazilian Ministry of Health (Ministério da Saúde): Responsible for the overall management and funding of the SUS, including defining guidelines and protocols for diagnostic procedures.
  - National Supplementary Health Agency (ANS): The regulatory body for the supplementary health sector, responsible for regulating health insurance operators and the services they cover, including diagnostic procedures.
  - Health Insurance Operators (e.g., Bradesco Saúde, SulAmérica, Amil, Hapvida): Large companies that offer health insurance plans and are significant payers for diagnostic services in the private sector. Hapvida is also involved in vertical integration, acquiring diagnostic services.
  - Various public hospitals and health centers: Providing diagnostic services within the SUS.
  - Private hospitals and clinics: Offering diagnostic services to their patients, often with integrated laboratory and imaging facilities.
Financing and Reimbursement: This step involves the flow of money within the value chain, including how diagnostic services are paid for.
- Identification and description of segments for each step of the value chain.
  - Segment: Public Funding. Resources allocated by federal, state, and municipal governments to the SUS for diagnostic services.
  - Segment: Private Insurance Funding. Payments made by health insurance operators to diagnostic service providers.
  - Segment: Direct Patient Payment. Out-of-pocket payments by patients.
- List of types of players in each segment
  - Government bodies (Ministry of Health, State and Municipal Health Secretariats).
  - Health insurance operators.
  - Patients.
- Detailed description of the main activities within each segment.
  - Public Funding: Budget allocation, defining reimbursement tables for procedures within the SUS.
  - Private Insurance Funding: Premium collection, claims processing, negotiation of payment rates with providers, risk management.
  - Direct Patient Payment: Patients paying for services at the time of delivery.
- List examples of key players with detailed profiles.
  - Mentioned under Healthcare Service Delivery and Utilization (Government bodies, Health Insurance Operators).
Regulation and Oversight: Although not a linear step, regulatory bodies and professional associations play a crucial role across the entire value chain, ensuring quality, safety, and ethical practices.
- Identification and description of segments for each step of the value chain.
  - Segment: Health Regulation. Encompasses the rules and standards for diagnostic products, services, and facilities.
  - Segment: Professional Regulation. Governs the practice of healthcare professionals involved in diagnostic medicine.
- List of types of players in each segment
  - National Health Surveillance Agency (ANVISA).
  - National Supplementary Health Agency (ANS).
  - Federal Councils of Medicine (CFM), Pharmacy, Biology, etc.
  - Professional associations (e.g., Sociedade Brasileira de Patologia, Sociedade Brasileira de Análises Clínicas).
  - Industry associations (e.g., Abramed - Associação Brasileira de Medicina Diagnóstica, ABIIS - Aliança Brasileira da Indústria Inovadora em Saúde).
- Detailed description of the main activities within each segment.
  - Health Regulation: Licensing and inspection of manufacturing facilities, distributors, and service providers; registering diagnostic products; setting standards for quality control and laboratory practices (e.g., RDC 786).
  - Professional Regulation: Defining requirements for professional training and licensing; establishing codes of ethics; overseeing professional conduct.
  - Industry Associations: Advocating for the interests of their members, promoting best practices, collecting market data, interacting with regulatory bodies.
- List examples of key players with detailed profiles.
  - ANVISA: The primary regulatory body for health products and services in Brazil, crucial for the approval and oversight of diagnostic devices and reagents.
  - ANS: Regulates the supplementary health market, impacting reimbursement policies and coverage of diagnostic procedures by health plans.
  - Abramed: An association representing diagnostic medicine companies in Brazil, playing a role in advocating for the sector and providing market data.
  - CFM: The body that regulates the medical profession in Brazil, including the activities of physicians involved in diagnostic interpretation and procedures.

Show estimates of volumes and sizes of each step in the value chain.¶

While precise volume and size data for each specific step of the value chain (manufacturing value vs. distribution value, etc.) are not available in granular detail from the provided sources, we can glean overall market sizes and service volumes:

Overall Diagnostic Medicine Market Size: The Brazilian in-vitro diagnostics market alone is estimated at US$ 2.12 billion in 2024, with a projected growth to US$ 2.87 billion by 2029 (CAGR of 6.12%). The broader market including imaging and other diagnostic services is significantly larger.
Service Volume: Brazilians underwent 2.4 billion diagnostic exams in 2023 through SUS and supplementary health, an 11% increase from 2022. Half of these (1.2 billion) were in the private sector, showing a 40% growth in the private sector volume between 2018 and 2023.
Supplementary Health Spending: In 2023, diagnostic procedures represented 21.1% of the expenses for supplementary health operators, a slight decrease from 22.9% in 2018, despite the increase in volume.
Market for Medical Devices and IVD: The Brazilian market for medical devices and in-vitro diagnostics grew by 57.9% between 2018 and 2023 (11.6% annually), reaching an estimated US$ 15.4 billion in 2023. 43.5% of this market consists of imported products.
Public Sector Volume (SUS): While a specific total volume for SUS in 2023 is not explicitly stated, the data indicates a significant volume, contributing to the 2.4 billion total exams. Afip Medicina Diagnóstica alone had a production value of R$ 145 million in the SUS outpatient network in 2021, representing 8% of the total outpatient production in Brazil and 49% in the city of São Paulo.
Anatomical Pathology Market: The global anatomical pathology market is expected to grow at a CAGR of 6.5% over the next 5 years. While a specific size for Brazil isn't given, it's a component of the overall diagnostic medicine market.

These figures highlight the significant scale and growth of the diagnostic medicine market in Brazil, driven by increased demand due to factors like the aging population and higher prevalence of chronic diseases.

Value Chain Summary Table¶

Value Chain Step	Main Activities	Segments	Types of Players	Examples of Key Players	Volumes/Sizes (Estimates)
Research, Development, and Manufacturing	Ideation, R&D, Production, Quality Control, Regulatory Approval	IVD Manufacturing, Medical Imaging Equipment Manufacturing, Anatomical Pathology Supplies Manufacturing, Software and IT Solutions Development	Multinational manufacturers, National manufacturers, Research institutions	Roche Diagnostics, Vyttra Diagnósticos, Biocon Diagnóstica, Labtest Diagnóstica, Gold Analisa Diagnóstica, Siemens Healthineers, GE Healthcare, Philips Healthcare	Brazilian IVD market estimated at US$ 2.12 billion in 2024. Brazilian medical devices and IVD market US$ 15.4 billion in 2023.
Distribution and Commercialization	Logistics, Warehousing, Sales, Marketing, Technical Support	Wholesale Distribution, Specialized Distribution, Direct Sales	National distributors, Regional distributors, Manufacturer's sales teams, Representatives	Vyttra Diagnósticos, Biocon Diagnóstica, Sullab, DNEDX, Inopat, Erba Mannheim Brasil	13,456 companies operate in distribution in the broader medical technology sector.
Diagnostic Service Provision	Sample Collection & Analysis, Imaging, Tissue Processing, Reporting, QC	Clinical Analysis Laboratories, Diagnostic Imaging Centers, Anatomical Pathology Laboratories, Genetics and Molecular Diagnostics, POCT Providers	Large national networks, Small/medium labs, Hospital labs/imaging, Public health labs, Diagnostic units	Dasa, Grupo Fleury, Sabin Medicina Diagnóstica, Afip Medicina Diagnóstica, Rede D'Or São Luiz	2.4 billion exams performed in 2023 (SUS + Supplementary). 1.2 billion exams in the private sector in 2023.
Healthcare Service Delivery & Utilization	Integration into healthcare, Patient/Physician access, Treatment Planning	Public Healthcare System (SUS), Supplementary Health System, Private Self-Pay, Corporate/Occupational Health	Public hospitals/units, Private hospitals/clinics, Health insurance operators, Companies, Patients, Physicians	Ministry of Health, ANS, Health Insurance Operators (Bradesco Saúde, SulAmérica, Amil, Hapvida), Public hospitals, Private hospitals/clinics	Supplementary health covers ~25% of the population. SUS serves the majority of the population.
Financing and Reimbursement	Funding allocation, Claims processing, Payment negotiation	Public Funding, Private Insurance Funding, Direct Patient Payment	Government bodies, Health insurance operators, Patients	Ministry of Health, State/Municipal Health Secretariats, Health Insurance Operators	Diagnostic procedures represent 21.1% of supplementary health expenses (2023). Afip's SUS outpatient production: R$ 145 million (2021).
Regulation and Oversight	Licensing, Inspection, Product Registration, Standards Setting, Professional Ethics	Health Regulation, Professional Regulation	ANVISA, ANS, Professional Councils (CFM, etc.), Professional Associations, Industry Associations	ANVISA, ANS, CFM, Abramed, ABIIS	Impacts all steps of the value chain; ensures quality and safety.

Examples of Main Players¶

Here are profiles of some of the most relevant players in the Diagnostic Medicine value chain in Brazil, illustrating their roles:

Dasa: As one of the largest integrated healthcare networks in Brazil, Dasa operates extensively in the Diagnostic Service Provision step. They have a vast network of clinical analysis laboratories and imaging centers across the country, offering a comprehensive portfolio of diagnostic tests. Their business model involves serving both the supplementary health market and private patients. They have been actively involved in mergers and acquisitions to expand their reach and service offerings.
Grupo Fleury: A prominent player in the Diagnostic Service Provision step, known for its focus on high-quality and specialized diagnostic medicine. Their merger with Hermes Pardini significantly consolidated the market. They operate a network of patient service centers and provide a wide range of laboratory and imaging tests, catering primarily to the supplementary health and private segments.
Roche Diagnostics: A key player in the Research, Development, and Manufacturing step, and also involved in Distribution and Commercialization. As a global leader in in-vitro diagnostics, Roche supplies a wide array of instruments and reagents to laboratories in Brazil. Their business model is centered on providing innovative diagnostic solutions and supporting laboratories with technology and expertise.
Afip Medicina Diagnóstica: Notable for its significant role in providing Diagnostic Service Provision within the public sector (SUS). They are highlighted as the largest clinical analysis laboratory in the SUS outpatient network. Their model includes serving both the public system and expanding into B2B services for other healthcare providers.

Volumes and Sizes¶

As detailed in the Value Chain outline section:

The Brazilian in-vitro diagnostics market is estimated at US$ 2.12 billion in 2024.
The broader market for medical devices and in-vitro diagnostics in Brazil reached an estimated US$ 15.4 billion in 2023.
A total of 2.4 billion diagnostic exams were performed in Brazil in 2023 across SUS and supplementary health.
The private sector accounted for 1.2 billion exams in 2023.
Diagnostic procedures represented 21.1% of supplementary health expenses in 2023.
Afip Medicina Diagnóstica's production in the SUS outpatient network was valued at R$ 145 million in 2021.

While specific market shares for individual players across all segments are not readily available in the provided sources, the mention of players like Dasa, Fleury (post-merger), and Sabin indicates significant consolidation and considerable market share held by larger networks in the Diagnostic Service Provision step.

References¶

Mordor Intelligence: Tamanho do mercado de diagnóstico in vitro do Brasil e análise de ações – Tendências e previsões de crescimento (2024 - 2029).
Vyttra Diagnósticos: soluções diagnósticas sem fronteiras. https://vyttra.com.br/
Shift: Tendências na medicina diagnóstica para 2025: inovação, eficiência e foco no paciente. https://medical.shift.com.br/tendencias-medicina-diagnostica-2025/
Associação Brasileira de Medicina Diagnóstica (Abramed): Pesquisa revela que brasileiros realizaram 2,4 bilhões de exames de diagnóstico em 2023.
Saúde Business: Medicina diagnóstica: perspectivas otimistas para o próximo ano. https://www.saudebusiness.com/gestao/medicina-diagnostica-perspectivas-otimistas-para-o-proximo-ano
Biocon Diagnósticos. https://biocon.com.br/
Sullab - Diagnósticos Clínicos. https://www.sullab.com.br/
Mobilemed: Tendências e desafios da Medicina Diagnóstica. https://mobilemed.com.br/tendencias-e-desafios-da-medicina-diagnostica/
Conrad: Perspectivas da medicina diagnóstica para 2025. https://conradweb.com.br/perspectivas-da-medicina-diagnostica-para-2025/
FGV EAESP: Impacto Da Criação Da Associação Brasileira De Medicina Diagnóstica (Abramed) Como Estratégia De Competitividade No Setor Privado De Serviços Diagnósticos No Brasil.
Roche: Diagnóstica - Roche. https://www.roche.com.br/pt/diagnostica.html
DNEDX: Home page. https://dnedx.com.br/
BioTécnica: Home. https://biotecnica.ind.br/
Terra: Fusões e aquisições no setor de saúde devem crescer este ano, com foco regional, diz consultoria. https://www.terra.com.br/economia/fusao-e-aquisicao/fusoes-e-aquisicoes-no-setor-de-saude-devem-crescer-este-ano-com-foco-regional-diz-consultoria,5156b31a6f66c4244878f249604280cahc8432oq.html
Percepção de Valor em Serviços de Medicina Diagnóstica. https://www.saudebusiness.com/gestao/percepcao-de-valor-em-servicos-de-medicina-diagnostica
Gestão da Inovação em Medicina Diagnóstica: um Estudo de Caso - Biblioteca Digital de Teses e Dissertações da USP. https://www.teses.usp.br/teses/disponiveis/5/5135/tde-10022016-112854/public/Leonardo_Bonato_Perez_Corrigida.pdf
Terra: Com crescimento de 25%, fusões e aquisições no setor de saúde quebram recorde. https://www.terra.com.br/economia/com-crescimento-de-25-fusoes-e-aquisicoes-no-setor-de-saude-quebram-recorde,72a1619778a872bb3f2529c7d709520by1u7137k.html
Futuro da Saúde: Medicina diagnóstica: o que esperar do setor nos próximos anos. https://futurodasude.com.br/medicina-diagnostica-o-que-esperar-do-setor/
A expansão dos laboratórios clínicos no Brasil: desafios para 2025. https://www.acclab.com.br/a-expansao-dos-laboratorios-clinicos-no-brasil-desafios-para-2025/
Afip: Afip lança unidade de negócios de medicina diagnóstica. https://www.afip.com.br/afip-lanca-unidade-de-negocios-de-medicina-diagnostica/
Revistas PUC-SP: O segmento da medicina diagnóstica no Brasil. https://revistas.pucsp.br/RFCMS/article/download/26500/18754/62758
Erba Mannheim Brasil – A ERBA Manheimm oferece soluções de diagnóstico de saúde humana de alto padrão com custo acessível. https://www.erbamanheim.com.br/
VEJA: Tendências da medicina para 2025: o que vai mudar nos exames | Letra de Médico. https://veja.abril.com.br/coluna/letra-de-medico/tendencias-da-medicina-para-2025-o-que-vai-mudar-nos-exames
CRM-PB: Anatomia Patológica: já ouviu falar?. https://www.crmpb.org.br/anatomia-patologica-ja-ouviu-falar/
Saúde Business: Fusões e aquisições no setor de saúde ganham impulso em 2024. https://www.saudebusiness.com/fusoes-e-aquisicoes/fusoes-e-aquisicoes-no-setor-de-saude-ganham-impulso-em-2024
Gold Analisa Diagnóstica - Produtos para uso diagnóstico in vitro - Minas Gerais - Brasil. https://goldanalisa.com.br/
Afip: O Dia Nacional da Filantropia, celebrado em 20 de outubro, é um bom momento para se observar os ganhos do trabalho realizado por entidades filantrópicas como a Afip Medicina Diagnóstica que, há mais de dez anos, é o maior laboratório de análises clínicas da rede ambulatorial do SUS. A marca pertence à AFIP. https://www.afip.com.br/o-dia-nacional-da-filantropia-celebrado-em-20-de-outubro-e-um-bom-momento-para-se-observar-os-ganhos-do-trabalho-realizado-por-entidades-filantropicas-como-a-afip-medicina-diagnostica-que-ha-mais-de-dez-anos-e-o/
Shopplab Notícias: O Mercado Brasileiro de Medicina Diagnóstica: um Panorama Atual. https://www.shopplab.com.br/blog/o-mercado-brasileiro-de-medicina-diagnostica-um-panorama-atual/
Portal Afya: Quais as expectativas de novidades para a área da saúde em 2025?. https://conteudos.afya.com.br/quais-as-expectativas-de-novidades-para-a-area-da-saude-em-2025
Estadão: Fusões e aquisições no setor de saúde disparam no 1º trimestre, diz PwC. https://www.estadao.com.br/economia/fusoes-e-aquisicoes-no-setor-de-saude-disparam-no-1-trimestre-diz-pwc/
Hospital Sírio-Libanês: Tendências da Saúde para 2025: novidades e o que deve vir. https://hospitalsiriolibanes.org.br/resources/publicacoes/tendencias-da-saude-para-2025-novidades-e-o-que-deve-vir
Hospital São Paulo: Saúde Suplementar. https://hospitalsaopaulo.org.br/saude-suplementar
Interfarma: Medicina diagnóstica tem papel decisivo na saúde suplementar.
BizNews Brasil: Fusão mexe com mercado de medicina diagnóstica: Fleury se une a Pardini e pode ultrapassar Dasa. https://biznews.com.br/fusaofleuryhermespardini/
Labtest Diagnóstica: Gestão Laboratorial: criando a estratégia para 2024. https://labtest.com.br/blog/gestao-laboratorial-criando-a-estrategia-para-2024/
Mordor Intelligence: Tamanho do mercado de patologia anatômica e análise de ações- Relatório de pesquisa da indústria- Tendências de crescimento.
Histocell: Soluções em Anatomia Patológica. https://histocell.com.br/
FORTA TECH: Equipamentos de diagnóstico e reparo para profissionais. https://fortatech.com.br/equipamentos-de-diagnostico/
Inopat: Conheça um pouco mais sobre nós e sobre nossos serviços. https://www.inopat.com.br/a-inopat/
Conselho Federal de Medicina: Aumento recorde no total de médicos no País pode ser cenário de risco para a assistência, avalia Conselho Federal de Medicina. https://portal.cfm.org.br/noticias/aumento-recorde-no-total-de-medicos-no-pais-pode-ser-cenario-de-risco-para-a-assistencia-avalia-conselho-federal-de-medicina/
Mordor Intelligence: Tamanho do mercado Diagnóstico por Imagem e Análise de Participação - Relatório de Pesquisa da Indústria - Tendências de Crescimento.
Medicina SA: Mercado de dispositivos médicos e diagnóstico in-vitro cresceu 57,9%. https://medicinasa.com.br/mercado-dispositivos-medicos/
Ministério da Saúde - Portal Gov.br: Protocolos Clínicos e Diretrizes Terapêuticas - PCDT. https://www.gov.br/saude/pt-br/assuntos/protocolos-clinicos-e-diretrizes-terapeuticas-pcdt
Biblioteca Virtual em Saúde MS: MEDICINA NUCLEAR; SUS; DIAGNÓSTICO POR IMAGEM; COMPOSTOS RADIOFARMACÊUTICOS; TOMOGRAFIA POR EMISSÃO DE PÓSITRONS COMBINADA À TOMOGRAFIA COMPUTADORIZADA; CINTILOGRAFIA. https://lil.bvsalud.org/na/ws/portalcs/document/view?id=1052846